AI assistant
Sending…
Marker Therapeutics, Inc. — Director's Dealing 2011
Sep 28, 2011
35150_dirs_2011-09-28_6e3d2604-e89b-4e01-a617-7304cc35782d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: TAPIMMUNE INC (TPIV)
CIK: 0001094038
Period of Report: 2010-09-07
Reporting Person: DePippo Lynn (Director)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 108696 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Purchase Options (Under the 2009 Stock Incentive Plan) | $0.17 | 2022-09-07 | Common Stock (250000) | Direct |
Footnotes
F1: The options to purchase 250,000 common shares were granted on September 7, 2010. 10,417 shares of such options vest each month for a total of 24 months.
More from Marker Therapeutics, Inc.
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
Mar 20
Annual Report
2026
Mar 20
Proxy Solicitation & Information Statement
2026
Mar 20
Annual Report
2026
Mar 18
Regulatory Filings
2026
Feb 9
Director's Dealing
2025
Nov 19
Director's Dealing
2025
Nov 19
Director's Dealing
2025
Nov 19
Major Shareholding Notification
2025
Nov 17